

# Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterola ...

---

Vallejo-Vaz, Antonio J.; Akram, Asif; Kondapally Seshasai, Sreenivasa Rao; Cole, Della; Watts, Gerald F.; Hovingh, G. Kees; Kastelein, John J.P.; Mata, Pedro; Raal, Frederick J.; Santos, Raul D.; ...

Source / Izvornik: **Atherosclerosis Supplements**, 2016, 22, 1 - 32

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1016/j.atherosclerosissup.2016.10.001>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:384933>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom](#).

Download date / Datum preuzimanja: **2024-11-30**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine](#)  
[Digital Repository](#)



## Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration

The EAS Familial Hypercholesterolaemia Studies Collaboration, Antonio J. Vallejo-Vaz<sup>a,\*</sup>, Asif Akram<sup>b,u</sup>, Sreenivasa Rao Kondapally Seshasai<sup>c</sup>, Della Cole<sup>c</sup>, Gerald F. Watts<sup>d</sup>, G. Kees Hovingh<sup>e</sup>, John J.P. Kastelein<sup>e</sup>, Pedro Mata<sup>f</sup>, Frederick J. Raal<sup>g</sup>, Raul D. Santos<sup>h</sup>, Handrean Soran<sup>i</sup>, Tomas Freiburger<sup>j,k</sup>, Marianne Abifadel<sup>l</sup>, Carlos A. Aguilar-Salinas<sup>m</sup>, Fahad Alnouri<sup>n</sup>, Rodrigo Alonso<sup>o</sup>, Khalid Al-Rasadi<sup>p</sup>, Maciej Banach<sup>q</sup>, Martin P. Bogstrup<sup>r</sup>, Mafalda Bourbon<sup>s</sup>, Eric Bruckert<sup>t</sup>, Josip Car<sup>b,u</sup>, Richard Ceska<sup>v</sup>, Pablo Corral<sup>w</sup>, Olivier Descamps<sup>x</sup>, Hans Dieplinger<sup>y</sup>, Can T. Do<sup>z</sup>, Ronen Durst<sup>aa</sup>, Marat V. Ezhov<sup>ab</sup>, Zlatko Fras<sup>ac,ad</sup>, Dan Gaita<sup>ae</sup>, Isabel M. Gaspar<sup>af</sup>, Jaques Genest<sup>ag</sup>, Mariko Harada-Shiba<sup>ah</sup>, Lixin Jiang<sup>ai</sup>, Meral Kayikcioglu<sup>aj</sup>, Carolyn S.P. Lam<sup>ak</sup>, Gustavs Latkovskis<sup>al</sup>, Ulrich Laufs<sup>am</sup>, Evangelos Liberopoulos<sup>an</sup>, Jie Lin<sup>ao</sup>, Nan Lin<sup>a</sup>, Vincent Maher<sup>ap</sup>, Nelson Majano<sup>aq</sup>, A. David Marais<sup>ar</sup>, Winfried März<sup>as</sup>, Erkin Mirrakhimov<sup>at</sup>, André R. Miserez<sup>au,av</sup>, Olena Mitchenko<sup>aw</sup>, Hapizah Nawawi<sup>ax</sup>, Lennart Nilsson<sup>ay</sup>, Børge G. Nordestgaard<sup>az</sup>, György Paragh<sup>ba</sup>, Zaneta Petrulioniene<sup>bb</sup>, Belma Pojskic<sup>bc</sup>, Željko Reiner<sup>bd</sup>, Amirhossein Sahebkar<sup>be</sup>, Lourdes E. Santos<sup>bf</sup>, Heribert Schunkert<sup>bg</sup>, Abdullah Shehab<sup>bh</sup>, M. Naceur Slimane<sup>bi</sup>, Mario Stoll<sup>bj</sup>, Ta-Chen Su<sup>bk</sup>, Andrey Susekov<sup>bl</sup>, Myra Tilney<sup>bm</sup>, Brian Tomlinson<sup>bn</sup>, Alexandros D. Tselepis<sup>bo</sup>, Branislav Vohnout<sup>bp</sup>, Elisabeth Widén<sup>bq</sup>, Shizuya Yamashita<sup>br</sup>, Alberico L. Catapano<sup>bs</sup>, Kausik K. Ray<sup>a</sup>

<sup>a</sup>Imperial Centre for Cardiovascular Disease Prevention (ICCP), School of Public Health, Imperial College London, London, UK

<sup>b</sup>Global eHealth Unit, School of Public Health, Imperial College London, London, UK

<sup>c</sup>Cardiovascular and Cell Sciences Research Institute, St George's, University of London, London, UK

<sup>d</sup>Cardiovascular Medicine, Royal Perth Hospital, University of Western Australia, Perth, Australia

<sup>e</sup>Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands

<sup>f</sup>Fundación Hipercolesterolemia Familiar, Madrid, Spain

<sup>g</sup>Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

<sup>h</sup>Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil

<sup>i</sup>University Department of Medicine, Central Manchester University Hospitals, Manchester, UK

<sup>j</sup>Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic

<sup>k</sup>Ceitec, Masaryk University, Brno, Czech Republic

<sup>l</sup>Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Saint-Joseph University, Beirut, Lebanon

<sup>m</sup>Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico

<sup>n</sup>Cardiovascular Prevention and Rehabilitation Unit, Prince Sultan Cardiac Centre Riyadh, Riyadh, Saudi Arabia

<sup>o</sup>Lipid Clinic, Department of Nutrition, Clínica Las Condes, Santiago de Chile, Chile

- <sup>p</sup> Sultan Qaboos University Hospital, Muscat, Oman
- <sup>q</sup> Department of Hypertension, Medical University of Lodz, Lodz, Poland
- <sup>r</sup> National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Norway
- <sup>s</sup> Instituto Nacional de Saúde Doutor Ricardo Jorge and Biosystems & Integrative Sciences Institute (BioISI), Universidade de Lisboa, Portugal
- <sup>t</sup> Endocrinologie, métabolisme et prévention cardiovasculaire, Institut E3M et IHU cardiométabolique (ICAN), Hôpital Pitié-Salpêtrière, Paris, France
- <sup>u</sup> Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
- <sup>v</sup> Charles University in Prague, Prague, Czech Republic
- <sup>w</sup> FASTA University, School of Medicine, Mar del Plata, Argentina
- <sup>x</sup> Centres Hospitaliers Jolimont, Haine Saint-Paul, Belgium
- <sup>y</sup> Austrian Atherosclerosis Society, c/o Division of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria
- <sup>z</sup> Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Viet Nam
- <sup>aa</sup> Hadassah Hebrew University Medical Centre, Jerusalem, Israel
- <sup>ab</sup> Russian Cardiology Research and Production Centre, Moscow, Russia
- <sup>ac</sup> University Medical Centre Ljubljana, Division of Medicine, Preventive Cardiology Unit, Ljubljana, Slovenia
- <sup>ad</sup> Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
- <sup>ae</sup> Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Romania
- <sup>af</sup> Medical Genetics Department, Centro Hospitalar de Lisboa Ocidental and Genetics Laboratory, Lisbon Medical School, University of Lisbon, Portugal
- <sup>ag</sup> McGill University, Montreal, Canada
- <sup>ah</sup> National Cerebral and Cardiovascular Centre Research Institute, Osaka, Japan
- <sup>ai</sup> National Clinical Research Centre of Cardiovascular Diseases, Fuwai Hospital, National Centre for Cardiovascular Diseases, Beijing, China
- <sup>aj</sup> Ege University Medical School, Department of Cardiology, Izmir, Turkey
- <sup>ak</sup> National Heart Centre Singapore and Duke-National University of Singapore, Singapore
- <sup>al</sup> Research Institute of Cardiology and Regenerative Therapy, Faculty of Medicine, University of Latvia, Paul Stradins Clinical University Hospital, Riga, Latvia
- <sup>am</sup> Universität des Saarlandes, Homburg, Germany
- <sup>an</sup> University of Ioannina Medical School, Ioannina, Greece
- <sup>ao</sup> Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
- <sup>ap</sup> Tallaght Hospital, Ireland
- <sup>aq</sup> Hospital Militar de Caracas, Caracas, Venezuela
- <sup>ar</sup> University of Cape Town and National Health Laboratory Service, South Africa
- <sup>as</sup> Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Germany
- <sup>at</sup> Kyrgyz State Medical Academy, Kyrgyzstan
- <sup>au</sup> Diogene GmbH, Research Institute, Reinach, Switzerland
- <sup>av</sup> Faculty of Medicine, University of Basel, Basel, Switzerland
- <sup>aw</sup> Dyslipidaemia Department, Institute of Cardiology AMS of Ukraine, Ukraine
- <sup>ax</sup> Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM) and Faculty of Medicine, Universiti Teknologi MARA, Malaysia
- <sup>ay</sup> Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
- <sup>az</sup> Herlev and Gentofte Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark
- <sup>ba</sup> Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, Hungary
- <sup>bb</sup> Vilnius University Santariskiu Hospital, Centre of Cardiology and Angiology, Vilnius, Lithuania
- <sup>bc</sup> Cantonal Hospital, Zenica, Bosnia and Herzegovina
- <sup>bd</sup> Department for Metabolic Diseases, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia
- <sup>be</sup> Biotechnology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
- <sup>bf</sup> Cardinal Santos Medical Centre, University of the Philippines – Philippine General Hospital (UP-PGH), Philippines
- <sup>bg</sup> Deutsches Herzzentrum München, Technische Universität München, Deutsches Zentrum für Herz- und Kreislauferkrankungen (DZHK), Munich Heart Alliance, Germany
- <sup>bh</sup> CMHS, UAE University, AlAin, United Arab Emirates
- <sup>bi</sup> Research Unit on Dyslipidaemia and Atherosclerosis, Faculty of Medicine of Monastir, Tunisia
- <sup>bj</sup> Cardiovascular Genetic Laboratory, Cardiovascular Health Commission, Montevideo, Uruguay
- <sup>bk</sup> Department of Internal Medicine and Cardiovascular Centre, National Taiwan University Hospital, Taipei, Taiwan
- <sup>bl</sup> Department of Clinical Pharmacology and Therapeutics, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russian Federation, Russia
- <sup>bm</sup> Faculty of Medicine & Surgery, Medical School, Mater Dei Hospital, University of Malta, Malta
- <sup>bn</sup> Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region
- <sup>bo</sup> Atherothrombosis Research Centre, University of Ioannina, Ioannina, Greece
- <sup>bp</sup> Coordination Centre for Familial Hyperlipoproteinemias, Institute of Nutrition, FOZOS, Slovak Medical University, Department of Epidemiology, School of Medicine, Comenius University, Bratislava, Slovakia
- <sup>bq</sup> Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
- <sup>br</sup> Rinku General Medical Centre and Osaka University Graduate School of Medicine, Osaka, Japan
- <sup>bs</sup> University of Milan and Multimedita IRCCS, Milan, Italy

---

## Abstract

**Background:** The potential for global collaborations to better inform public health policy regarding major non-communicable diseases has been successfully demonstrated by several large-scale international consortia. However, the true public health impact of familial

hypercholesterolaemia (FH), a common genetic disorder associated with premature cardiovascular disease, is yet to be reliably ascertained using similar approaches. The European Atherosclerosis Society FH Studies Collaboration (EAS FHSC) is a new initiative of international stakeholders which will help establish a global FH registry to generate large-scale, robust data on the burden of FH worldwide.

**Methods:** The EAS FHSC will maximise the potential exploitation of currently available and future FH data (retrospective and prospective) by bringing together regional/national/international data sources with access to individuals with a clinical and/or genetic diagnosis of heterozygous or homozygous FH. A novel bespoke electronic platform and FH Data Warehouse will be developed to allow secure data sharing, validation, cleaning, pooling, harmonisation and analysis irrespective of the source or format. Standard statistical procedures will allow us to investigate cross-sectional associations, patterns of real-world practice, trends over time, and analyse risk and outcomes (e.g. cardiovascular outcomes, all-cause death), accounting for potential confounders and subgroup effects.

**Conclusions:** The EAS FHSC represents an excellent opportunity to integrate individual efforts across the world to tackle the global burden of FH. The information garnered from the registry will help reduce gaps in knowledge, inform best practices, assist in clinical trials design, support clinical guidelines and policies development, and ultimately improve the care of FH patients.

© 2016 Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** Familial hypercholesterolaemia; LDL-Cholesterol; Cardiovascular disease; Registry; Study design; Familial Hypercholesterolaemia Studies Collaboration

## 1. Introduction

Familial hypercholesterolaemia (FH) is a common genetic disorder affecting low-density lipoprotein cholesterol (LDL-C) metabolism, resulting in reduced catabolism of LDL particles and marked elevations in circulating LDL-C [1–4]. If untreated, lifelong exposure to elevated LDL-C results in the development of atherosclerotic lesions early in life and a substantially increased risk of premature cardiovascular disease as compared to the general population [1–6]. In contrast, early detection and effective treatment of FH can result in a significant improvement in clinical outcomes [7,8]. Despite these compelling data, FH remains largely underdiagnosed with less than 5% of individuals with FH being identified in most regions around the world [1]. Compounding its burden is the observation that FH is undertreated even among those with an established diagnosis [1,9–11]. Moreover, an increase in the evidence-based recommendations for the detection and treatment of patients with FH to reduce cardiovascular risk are needed: whereas the class of recommendations for FH in lipid guidelines is high, the grade of evidence still falls frequently into level C [12].

## 2. Rationale for the EAS FHSC

The reasons behind underascertainment of FH cases are complex. They include an underappreciation of the true prevalence of FH. For instance, the prevalence of heterozygous FH (HeFH) was traditionally considered to be approximately 1:500 individuals [1]. However, in many cases these figures arose from the extrapolation of a limited amount of data from selected populations or specific subgroups to the general population and therefore may be unreliable [13]. By comparison, contemporary clinical and

genetic studies suggest that HeFH affects approximately 1:200–250 individuals [1,9,14–17], implying that up to over 30 million individuals could be affected worldwide [1]. Additionally, the prevalence of FH can vary substantially depending on how FH is defined (i.e. LDL-C threshold only, mutation definition only, both, or clinical score composed of several factors) [17]. Similarly, the observed undertreatment may in part be due to suboptimal use of available therapies for reasons that are unclear but may also include a lack of knowledge about the risks of sub-optimal therapy, concerns about the safety of available therapies, a lack of available therapies, or even a paucity of specialists and established guidelines and standards of care locally. Whilst lipid lowering therapies such as statins are potent, the high lifetime burden of risk from LDL-C elevations means that the impact from any therapeutic intervention is likely to be modest and significantly undermined when delays in the detection of FH and initiation of pharmacological therapies occur [1,10,18]. Additionally, the risk of cardiovascular events may also be influenced by additional factors not always completely addressed or recognised, e.g. lipoprotein(a) [19,20].

Underappreciation of the prevalence of FH and the adverse consequences of current clinical practice has ultimately resulted in a general lack of health policies aimed specifically at FH and a lack of awareness and education among health-care professionals and policy-makers [21]. Efforts to tackle the global burden of FH have been hindered by a lack of global cohesion. Firstly, the lack of uniformity among different initiatives, FH definition and ascertainment methods (e.g. opportunistic/cascade/universal screening; clinical/genetic diagnosis; different clinical criteria; prior absence of a unifying WHO “International Classification of Diseases” code for FH) [1,4,21–26] leads to variability in clinical practice, makes cross-health systems learning difficult, and



complicates reliable comparisons and harmonisation efforts. Secondly, data on FH is held in disparate formats across many sites/countries, resulting in fragmentation and lack of harmonised data from different cohorts [21,26]. A lack of structure and the availability of limited resources have made it hitherto difficult to integrate these cohorts, preventing researchers from scaling up current data and failing to achieve the potential of big data.

The gap in healthcare provision, knowledge and effective strategies requires a collective effort harnessing the combined potential of individual cohorts across the globe. For instance, the potential for global collaborations to inform public health policy reliably about major non-communicable diseases has been successfully demonstrated by international consortia such as the Non-Communicable Diseases consortium or the Emerging Risk Factors collaboration [27–31]. In this context, the European Atherosclerosis Society FH Studies Collaboration (EAS FHSC) is being developed as an ambitious international initiative to gather data derived from FH focused efforts from investigators worldwide [21]. The development of this wide collaborative network of investigators from different regions and countries will support an international large-scale FH registry and improve reliability of data on current clinical practices and corresponding outcomes. A strategic data sharing and integration plan will be implemented to efficiently combine data residing in different sources and formats, bring disparate data silos together, and provide for the first time a unified view of these large combined datasets.

Sharing and pooling the data in a structured systematic approach will allow us to overcome previous barriers and limitations to international comparisons across different cohorts [32–36], such as the heterogeneity, diversity and complexity of the data and standards used. It will align international efforts and help reduce redundant research, avoid duplication of efforts, and reduce costs of research. It will allow us to assess questions which cannot be addressed in individual studies, and provide greater precision in answering these questions than hitherto possible. Moreover, it will unveil additional findings beyond the original hypotheses tested, facilitate exploratory approaches due to the large sample size and generate new hypotheses. It may permit us to detect previously unobservable effects otherwise undetected in limited individual studies. Finally, it will increase the precision of estimates and investigate different patterns, trends and subgroup effects [32–36]. The diversity of the source of these data will also help provide unique and hitherto unavailable insights regarding regional and global variations in clinical practice, which may in turn be due to overt (e.g. health care delivery systems and other patient-, socio-economic- or treatment-related factors) or covert (subtle differences in population genetics) differences across populations.

Thus, information gained from the EAS FHSC will eventually help support and strengthen the evidence-based

decision-making process, overcome existing gaps in the management of FH, and inform health policies and clinical guidelines development.

### 3. EAS FHSC aims

The EAS FHSC is a global initiative of stakeholders involved in the care of people living with FH that seeks to empower the medical and global community to seek changes in their respective countries or organisations to promote early diagnosis and effective treatment of FH. Specifically, the EAS FHSC aims to:

- Establish a worldwide, standardised registry of patients with FH by bringing together regional/national/international cohorts and registries with access to FH patients. This will allow the collaboration to maximise the exploitation of the data to accurately and reliably investigate (i) the burden of both homozygous FH (HoFH) and HeFH, (ii) how FH is detected and managed, (iii) the clinical consequences of current practice on delivery of care and outcomes, (iv) the factors that influence optimal management and LDL-C target attainment in FH.
- Disseminate the information gained from the registry to an international audience including physicians, other healthcare professionals, policy-makers and patients' organizations, to sensitise them to the contemporary burden of FH, encourage open discussion on FH management, promoting a uniform evidence-based standard-of-care, and encourage them to contribute actively to research.
- Consolidate a network of investigators interested in FH through which collaborative research and networking on FH can be conducted on a large-scale.

The EAS FHSC registry has been conceived with a long-term strategy in mind, in order to increase the follow-up of patients, including new individuals diagnosed with FH over time, bringing new cohorts into the registry, and take into account temporal trends and changes in clinical practice, so that the findings remain relevant. As such, the project is expected to evolve over time as it will be further developed and expanded: we will continuously employ the best data sharing strategies and optimise the operational protocols based on the experience of the collaboration, number of participants included, results from the first waves of data collated, evolving aims, resources available, and feedback for those utilizing the data and the feedback from the wider medical community. The EAS FHSC protocol is shown in [Appendix 1](#).

### 4. EAS FHSC operational structure (Fig. 1)

The EAS FHSC is in the first instance governed by a panel of experts on FH who form the *Executive Committee* that

represents the academic leadership for this initiative (Appendix 2). The Executive Committee represents the core group for overarching management decisions, driving the collaboration, obtaining support and funding to ensure sustainability, and will evaluate the proposals for research, data mining, and expansion of the EAS FHSC.

The *Steering Committee* represents the advisory committee to provide guidance on the project development. It consists of all those investigators/stakeholders/experts appointed as EAS FHSC *National Lead Investigators/Country-leads* (NLI/CLs) for their respective countries/regions (Appendix 3). The NLI/CLs act as national leaders for the EAS FHSC within their respective countries or regions; as such they coordinate and are responsible for the identification and collaboration from the individual sites within their country/region, encouraging participation of other national physicians and researchers in the collaboration, liaising with relevant societies and patients' organisations, getting appropriate local approvals and permissions as needed, and gathering data from the respective region/country for transfer to the Coordinating Centre.

The *Coordinating Centre* is based at the Imperial Centre for Cardiovascular Disease Prevention (ICCP), Imperial College London (ICL), UK. It acts as the central point for data collation, management, standardisation, consolidation, analyses and queries, and it communicates, supports and coordinates the activities of the investigators involved. The Coordinating Centre will ensure the computational tools needed to share, collate and manage the data and will make use of analytical partners (e.g. informatics, biostatistics) to ensure the accurate generation of results.

Stakeholders with access to data on FH patients and data sources are identified through a review (Medline, EMBASE) of relevant published articles and hand search of papers and reports, through contact with national/international scientific societies, and through face-to-face meetings at major conferences. These investigators are approached and invited to join to the EAS FHSC as NLI/CLs after an initial assessment to establish the scope and characteristics of their data source. This decision is based on a combination of factors including, but not restricted to: estimates of the number of FH patients; information regarding how patients are managed and what key policies/methods underpinned their management decisions (e.g. whether cascade screening is carried out, whether genetic testing is available, etc.); capacity and resources available to lead EAS FHSC-related activities and coordinate other contributing investigators within their country/region; willingness to participate and conform to the local and project data management safeguard. At the time of the present submission, there were NLI/CLs investigators formally involved from over 50 countries worldwide (Fig. 2), including those coming directly to the EAS FHSC and from partnerships between the EAS FHSC and other related initiatives, i.e. the 10 Countries Study and the ScreenPro FH programme (Appendix 3).

## 5. EAS FHSC methodology

Data from multiple cohorts, registries, databases and collections with access to information on individuals with a clinical and/or genetic diagnosis of HoFH or HeFH will




Fig. 1. EAS FHSC operational/governance structure.




Fig. 2. Countries with investigators formally involved in the EAS FHSC (updated at the time of the present submission) Map created with [mapchart.net](http://mapchart.net).




Fig. 3. Data workflow and FH Data Warehouse. **(A)** Individual investigators from each local site will contribute to the FH registry through the National Lead Investigators/Country-leads (NLI/CLs) for each region or country. These NLI/CLs will transfer and upload the data to the Coordinating Centre through a bespoke secure web portal. **(B)** The FH Data Warehouse will be a complete platform supporting various research activities and thus will be composed of the following components: Web Portal for Data Collection; Data Validation; Data Collation; Data Analysis Tools; Web Portal for Reporting; Data Storage; Privacy Tool; Data Management Workflow; Workflow Monitoring; Logging Tool. **(C)** Multi Stage Data Storage for enhanced Security: Data Extraction; Web Portal for Data Collection; Temporary Data Server for Data Storage; Intermediary Data Server for Data Harmonisation; Secure Data Server for Data Warehouse; Application Server for Data Analysis and Reports. See [Appendix 1](#) for a detailed description.

be merged and harmonised into the global EAS FHSC registry. Investigators from the local sites will contribute to the FH registry through the NLI/CLs for the corresponding region or country. The latter will transfer and upload the data to the Coordinating Centre to be incorporated into the FH registry (Fig. 3A).

In order for the investigators to provide reliable data for inclusion into the registry, a set of minimum predefined quality and operational criteria have been laid out (Table 1), which must be satisfied by individual contributing cohorts. A minimum set of data (core data) are required for inclusion in the registry, comprising general and demographic information, familial and personal cardiovascular history, FH diagnostic criteria, lipid-lowering medication with doses, laboratory lipid profile, and clinical outcomes if follow-up data are available (retrospective or prospective). Where genetic tests are available, these genetic data form part of the core data requested; in case of HoFH, data about LDL-apheresis are also collected. Additionally, where available, a number of other parameters of interest will be

collected (Appendix 1). Where possible, standardised field definitions will be used and free entry text avoided. Our main long-term outcomes of interest will include all-cause and cardiovascular mortality and fatal/non-fatal cardiovascular events. Nevertheless, given the unique nature of the EAS FHSC database, information on factors such as statin intolerance, incident diabetes, aortic valve/supravalvular disease or cancer will be also sought and analysed. Updates of the shared datasets will be encouraged to be provided within a reasonable time-frame.

For each cohort/dataset a two-stage approach is followed: the first step comprises the collation of the cross-sectional and retrospective data readily available; the second stage involves the integration of longitudinal, prospective records and follow-up.

### 5.1. Data management

Management of this large volume of data securely will require the development of an informatics platform, which requires various steps from designing data models, collection, validation, harmonisation, transformation and analysis and reporting.

In the first instance, a secure web portal will be developed for the datasets to be transferred to the Coordinating Centre to provide an automated solution for data transfer, visualization and coordination. Data sharing plans involve instructions to the lead investigators for data to be transferred and data to be collected, updated with feedback for the individual investigators providing the data.

The preliminary data shared will be checked for consistency and accuracy by at least 2 independent investigators of the Coordinating Centre (scientific coordinator, data manager) and any discrepancies will be resolved by raising queries with the individual investigators. After ensuring satisfactory data quality, the information will be saved and harmonised into a bespoke central database (FH Data Warehouse [FHDW]) securely hosted on a university server by the Coordinating Centre, in strict adherence with all data safety protocols and regulatory requirements. The Coordinating Centre, supported by a technical team, will develop cutting edge and artificially intelligent routines incorporating machine learning for automated data cleaning, harmonising and make the data uniform and compatible. The data architecture and platform will support secure incorporation of data irrespective of source or format from multiple global repositories/databases/file systems allowing: data cleaning, validation, quality control and merging into the FHDW; retrospective and ongoing prospective data pooling, harmonisation and analysis. Regular monitoring of various stages of data flow will ensure that appropriate quality standards are maintained and that any deviations from protocols are immediately reported and rectified. The resource will make use of existing standards for wider user acceptance, technical interoperability and scalability. Regular surveys of the users' (i.e. lead investigators')

Table 1

EAS FHSC Registry: predefined quality and operational criteria for inclusion/exclusion of data to be shared.

(i)	The data must be in electronic format.
(ii)	The amount of data shared should be considered enough to add relevant information to the registry.
(iii)	The data must have been collected rigorously following a standardised well-designed protocol; inclusion and exclusion criteria must be well defined; FH must be well defined according to accepted criteria and not rely only on self-reported history of FH; any measurements recorded must have been done with validated and standardised methods and devices; standardised definitions should have been used; the data source/participants included should be representative of the target population.
(iv)	The parameters recorded must include at least the minimum set of data (core information) as specified in the protocol.
(v)	Local ethical and security aspects must be in place; a data sharing agreement must be signed prior to any data transfer.
(vi)	Data must conform with the inclusion/exclusion criteria:
Inclusion criteria	<ul style="list-style-type: none"> <li>(i) Individuals with a diagnosis of heterozygous or homozygous FH. <ul style="list-style-type: none"> <li>■ Diagnosis: clinical and/or genetic.</li> <li>■ Also including positive clinical diagnosis with negative genetic test and vice versa.</li> <li>■ In case of clinical diagnosis: <ul style="list-style-type: none"> <li>- Criteria used: Dutch Lipid Clinics Network, MedPed, Simon-Broome, Japanese criteria, or other to be specified.</li> <li>- Categories of possible, probable and confirmed FH.</li> </ul> </li> </ul> </li> <li>(ii) Relatives of index cases without a diagnosis of FH where screening (cascade or other) is carried out. <ul style="list-style-type: none"> <li>■ Secondary causes of dyslipidaemia (e.g. untreated hypothyroidism, cholestasis, nephrotic syndrome).</li> <li>■ Where data collation does not conform to the local or country wide standards for anonymised data.</li> </ul> </li> </ul>
Exclusion criteria	



experience will capture their expectations and obtain key suggestions and feedback, allowing appropriate adaptation and improvements of the user/resource interface, enhancing end-user experience for ease-of-use and efficient data management, allowing the resource to properly grow and evolve.

The overall structure of the FHDW and platform is shown in Fig. 3B/C. A detailed description is reported in Appendix 1 (protocol).

## 5.2. Analysis plan

After ensuring consistency and compatibility of the information and description of the variables, the data from various providers will be merged and analysed at an individual level as a composite dataset. Where this is not possible, analyses will be undertaken at a country/provider level, by analysing each dataset individually and then pooling the results together.

We will conduct different types of analyses, such as assessing the validity of previous published findings with greater power and precision, conducting alternative analyses of the same data, cross-cohort comparisons, analysing unpublished data (not previously conducted due to low sample size within each separate dataset), conducting exploratory analyses to generate new research hypotheses, etc.

We will analyse the data to address a number of research questions as shown in Table 2 [37,38]. Standard validated statistical procedures and models for observational studies and weighted meta-analyses (individual participant data meta-analysis where possible; meta-analysis of aggregated data alternatively) will be applied. Statistical methods described in studies such as the Emerging Risk Factors Collaboration [39,40] or the Non-Communicable Diseases Risk Factor Collaboration [27] will be used where appropriate. After exploratory analyses with description of the variables of interest, cross-sectional analyses and correlates will be performed. Comparisons of continuous parameters will be done with parametric and non-parametric tests as appropriate and categorical variables using Chi-squared test. We will quantify various exposure-outcome associations (unadjusted and adjusted) and epidemiological interactions using standard regression models. Risk prediction models using measures of discrimination (concordance index [C-index], discrimination measure [D-measure]) and reclassification (net reclassification index [NRI]) are intended to be performed. Cox proportional hazards regression models stratified by certain variables of interest (e.g. by gender, country, etc.) and Kaplan–Meier estimates of survival will be generated where time-to-event data is available.

Table 2

EAS FHSC scientific research questions.

- The EAS FHSC aims to establish an international registry of studies on FH with a view to better quantifying more reliably than hitherto possible:
- 1 How FH patients are detected, comparison of different proposed diagnostic criteria, whether current screening strategies for FH are adequate and, if not, what could be done differently to maximise coverage.
  - 2 How patients are managed, treatments offered/advised, how their efficacy is monitored.
  - 3 What proportion of FH patients meet the targets (e.g. LDL-C goals, patients receiving therapy), the impediments in attaining LDL-C goals, the role played by societal factors (such as access to healthcare in different settings and the availability of specialist advice) in enabling treatment to achieve LDL-C goal, the influence of gene–drug interactions in attaining LDL-C goals.
  - 4 Long-term risk of outcomes in patients with FH (including, where possible, estimates of the years lost due to FH), with a special focus on the following end-points:
    - Primary end-point 1: the composite of Cardiovascular Disease Events (fatal and non-fatal).
    - Primary end-point 2: Cardiovascular mortality.
    - Primary end-point 3: All-cause mortality.
    - Secondary end-points:
      - Each component of the Cardiovascular Disease Events end-point separately.
      - Aortic valve and supra-aortic disease.
      - Statin intolerance (clinical, biochemical).
      - New onset of diabetes.
      - Cancer diseases.
      - Pregnancy outcome in female patients with FH.
  - 5 To establish the value of incorporating genetic data and other factors (e.g. lipoprotein[a]) into the clinical diagnosis of FH and estimation of the risk of outcomes.
  - 6 The impact of patient-specific factors, socio-economic factors and treatment-related factors on LDL-C goal attainment and cardiovascular risk.
  - 7 Potential variations depending on different geographic settings as a result of factors such as population genetics, health care delivery systems and other patient-, socio-economic- or treatment-related factors.
  - 8 Where possible, evidence for economic evaluation of different screening strategies and of interventions will be addressed.

The following definitions shall apply: (i) Cardiovascular disease events: the composite of fatal and non-fatal coronary heart disease/acute coronary syndrome/myocardial infarction, cardiac sudden death, fatal and non-fatal stroke, transient ischaemic attack, peripheral vascular disease, and revascularization (percutaneous or surgical); (ii) Aortic valve disease: confirmed by any imaging test; (iii) Statin intolerance (clinical and/or biochemical): defined according to the EAS consensus panel [37]; (iv) New onset of diabetes mellitus: fasting glycaemia >126 mg/dL at least in two separate occasions, glycosylated haemoglobin  $\geq$ 6.5% (48 mmol/mol), and/or patient receiving a new prescription of an antidiabetic drug [38].

Measures of heterogeneity and risk of bias (e.g. regression dilution over time) will be applied.

We will account for different variables of interest, carry out appropriate adjustments systematically for potential confounders, consider key subgroups and correct for differences in definitions. Where feasible, reliable,

and data available we will also try to roughly approximate the prevalence of FH by extrapolating the data to the general population. The different sources of incoming data will also help assess potential variations depending on different geographic settings, including factors such as population genetics, healthcare delivery systems and other patient-, socio-economic- or treatment-related factors.

Following a “database-query” model [34], investigators involved in the registry will be able to submit research questions they would like to assess through the Coordinating Centre; if the request is deemed to be scientifically relevant by the Executive Committee and considered feasible by the Coordinating Centre, the latter will construct and run the analyses and return the results to the requester.

## 6. Ethics, security and regulatory considerations

This project and related research will be conducted in accordance with the principles of the Declaration of Helsinki. Where required, approval from the corresponding ethical and/or research committees and informed consent from participants will be requested by the investigators to collect, transfer and share the data. Data sharing agreements will be executed between the NLI/CLs sharing the data and the Coordinating Centre as the recipient of the data (Appendix 4).

The investigators and the Coordinating Centre will use all reasonable safeguards in connection with any transfer, communication or remote access connectivity involving the data. A secure web portal will be developed as a means for data entry/coordination and controlled environment. Only de-identified, pseudo-anonymised data will be collected, and removal of identifiers, replacement of dates with time intervals where possible, and categorization of several characteristics will be performed. A Global Unique Identifier will be assigned to each subject enabling investigators to follow their own subjects over time.

Data servers physically hosted by ICL will be encrypted to standards utilizing appropriate infrastructure; the database will be configured to be accessed only from approved terminals/computers. The data storage and handling will be compliant with the European Data Protection Act.

## 7. Dissemination and communication

The dissemination and exploitation plan will aim to maximise the spread of the results within a wide, large and diverse audience and to make the most of the information gained from the global FH registry. The means of

dissemination will be varied and tailored to the target audience, making use of the different resources available (including eHealth resources) in order to reach and impact stakeholders involved in the care of FH patients at multiple levels. The target audience will include physicians and other healthcare providers, investigators, FH patients and their relatives through the patients’ organisations, policy-makers, and, in general, the entire medical community. As all of these groups are potential users of the information generated we will aim to reach them all to ensure that the state-of-the-art information released is utilized to reduce gaps in knowledge and improve clinical practice for FH patients. The dissemination plan will include a number of components, such as publication of results in the form of reports and scientific articles in peer-reviewed high-impact international journals; communication of results at major conferences; academic dissemination; web and social media dissemination; press releases; engagement with patients’ organisations; where possible, engagement with policy-makers/health authorities; networking events (meetings, web forum).

## 8. Conclusions

The EAS FHSC initiative was formally launched during the 83rd EAS Congress in March 2015. Since then, a vast network of collaborators have formally committed themselves to join the EAS FHSC initiative; it is expected that other regions may follow suit as the project evolves, making the EAS FHSC an internationally leading registry for FH at the forefront of FH research.

The EAS FHSC initiative represents an excellent opportunity to integrate efforts across the world to tackle the global burden of FH. The large, cross-national, robust information generated from the FH registry will help narrow gaps in knowledge, inform the medical community about real-world and best practices, assist in clinical trials design, and support clinical guidelines and policy development. Ultimately, it will help prevent adverse outcomes and improve care of FH patients.

## Conflicts of interests

See Appendix 5.

## Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.atherosclerosis.2016.10.001>.



## Financial support and acknowledgments

The present project has received support from a Pfizer Independent Grant for Learning & Change 2014 (No: 16157823) and from investigator initiated unrestricted research grants to the European Atherosclerosis Society from Amgen, MSD, and Sanofi-Aventis. The project in Latvia was supported by the Latvian State Research Programme BIOMEDICINE. The project in Czech Republic was partly supported by grants MZ CR AZV 15-28277A and 16-29084A.

The funders had no role and no influence on the study design; analysis plan; participation and contribution of stakeholders/investigators; collection of data; interpretation of data; writing of the report; and decision to submit the paper for publication.

The Executive Committee of the EAS FHSC initiative and the corresponding authors confirm that they have had full access to the content of this manuscript and have final responsibility for the decision to submit the present report for publication.

## Authors' contributions

KKR, AJVV, SRKS, and DC conceived and designed the initiative and coordinate the project. JC and AA coordinate and will develop the IT technical aspects of the project. All authors take a role in the project either as Executive Committee, Steering Committee or Coordinating Centre investigators. Most authors have participated in discussions and meetings to discuss and define the project. KKR and AJVV wrote the draft of the article. All authors critically reviewed and approved the present article.

## References

- [1] Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013;34:3478–3490a. <http://dx.doi.org/10.1093/eurheartj/ehv273>.
- [2] Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J* 2014;35:2146–57. <http://dx.doi.org/10.1093/eurheartj/ehu274>.
- [3] Wiegman A, Gidding SS, Watts GF, Ginsberg HN, Cuchel M, Ose L, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J* 2015;36:2425–37. <http://dx.doi.org/10.1093/eurheartj/ehv157>.
- [4] Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol* 2011;5:S9–17. <http://dx.doi.org/10.1016/j.jacl.2011.03.452>.
- [5] Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierød MB, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992–2010. *J Am Heart Assoc* 2014;3:e001236. <http://dx.doi.org/10.1161/JAHA.114.001236>.
- [6] Krogh HW, Mundal L, Holven KB, Retterstøl K. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. *Eur Heart J* 2016;37:1398–405. <http://dx.doi.org/10.1093/eurheartj/ehv602>.
- [7] Braamskamp MJ, Kastelein JJ, Kusters DM, Hutten BA, Wiegman A. Statin initiation during childhood in patients with familial hypercholesterolemia: consequences for cardiovascular risk. *J Am Coll Cardiol* 2016;67:455–6. <http://dx.doi.org/10.1016/j.jacc.2015.11.021>.
- [8] Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ* 2008;337:a2423. <http://dx.doi.org/10.1136/bmj.a2423>.
- [9] Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab* 2012;97:3956–64. <http://dx.doi.org/10.1210/jc.2012-1563>.
- [10] Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. *Atherosclerosis* 2010;209:189–94. <http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.014>.
- [11] Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñoz O, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up. *J Am Coll Cardiol* 2016;67:1278–85. <http://dx.doi.org/10.1016/j.jacc.2016.01.008>.
- [12] Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2016. <http://dx.doi.org/10.1093/eurheartj/ehw272> [Epub ahead of print].
- [13] Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. *Am J Epidemiol* 2004;160:407–20. <http://dx.doi.org/10.1093/aje/kwh236>.
- [14] Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98,098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. *Eur Heart J* 2016;37:1384–94. <http://dx.doi.org/10.1093/eurheartj/ehw028>.
- [15] Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. *Eur Heart J* 2015;36:560–5. <http://dx.doi.org/10.1093/eurheartj/ehu058>.
- [16] Do R, Stitzel NO, Won HH, Jørgensen AB, Duga S, Merlini PA, et al. Exome sequencing identifies rare LDLR and APOA5 alleles

- conferring risk for myocardial infarction. *Nature* 2015;518:102–6. <http://dx.doi.org/10.1038/nature13917>.
- [17] Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J Am Coll Cardiol* 2016;67:2578–89. <http://dx.doi.org/10.1016/j.jacc.2016.03.520>.
- [18] Reiner Z. Management of patients with familial hypercholesterolaemia. *Nat Rev Cardiol* 2015;12:565–75. <http://dx.doi.org/10.1038/nrcardio.2015.92>.
- [19] Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010;31:2844–53. <http://dx.doi.org/10.1093/eurheartj/ehq386>.
- [20] Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. *J Am Coll Cardiol* 2014;63:1982–9. <http://dx.doi.org/10.1016/j.jacc.2014.01.063>.
- [21] Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJ, Mata P, et al. Familial hypercholesterolaemia: a global call to arms. *Atherosclerosis* 2015;243:257–9. <http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021>.
- [22] Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. *Eur Heart J* 2013;34:962–71. <http://dx.doi.org/10.1093/eurheartj/ehu015>.
- [23] Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. *J Clin Lipidol* 2014;8:148–72. <http://dx.doi.org/10.1016/j.jacl.2014.01.002>.
- [24] Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, et al. Guidelines for the management of familial hypercholesterolemia. *J Atheroscler Thromb* 2012;19:1043–60. <http://dx.doi.org/10.5551/jat.14621>.
- [25] World Health Organization (WHO). International Classification of Diseases (ICD) – 10. Version 2015. <http://apps.who.int/classifications/icd10/browse/2015/en>. [Accessed June 2016].
- [26] Hammond E, Watts GF, Rubinstein Y, Farid W, Livingston M, Knowles JW, et al. Role of international registries in enhancing the care of familial hypercholesterolaemia. *Int J Evid Based Healthc* 2013;11:134–9. <http://dx.doi.org/10.1111/1744-1609.12023>.
- [27] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513–30. [http://dx.doi.org/10.1016/S0140-6736\(16\)00618-8](http://dx.doi.org/10.1016/S0140-6736(16)00618-8).
- [28] Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009;302:1993–2000. <http://dx.doi.org/10.1001/jama.2009.1619>.
- [29] Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011;364:829–41. <http://dx.doi.org/10.1056/NEJMoa1008862>.
- [30] Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012;307:2499–506. <http://dx.doi.org/10.1001/jama.2012.6571>.
- [31] Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. *JAMA* 2014;311:1225–33. <http://dx.doi.org/10.1001/jama.2014.1873>.
- [32] Institute of Medicine (IOM). Sharing clinical trial data: maximising benefit, minimizing risks. Washington, DC: The National Academies Press; 2015. <http://dx.doi.org/10.17226/18998>.
- [33] Antman EM, Benjamin EJ, Harrington RA, Houser SR, Peterson ED, Bauman MA, et al. Acquisition, analysis, and sharing of data in 2015 and beyond: a survey of the landscape: a conference report from the American Heart Association data summit 2015. *J Am Heart Assoc* 2015;4(11):e002810. <http://dx.doi.org/10.1161/JAHA.115.002810>.
- [34] Coady SA, Wagner E. Sharing individual level data from observational studies and clinical trials: a perspective from NHLBI. *Trials* 2013;14:201. <http://dx.doi.org/10.1186/1745-6215-14-201>.
- [35] Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for responsible sharing of clinical trial data. *N Engl J Med* 2013;369:1651–8. <http://dx.doi.org/10.1056/NEJMp1309073>.
- [36] Krumholz HM. Open science and data sharing in clinical research: basing informed decisions on the totality of the evidence. *Circ Cardiovasc Qual Outcomes* 2012;5:141–2. <http://dx.doi.org/10.1161/CIRCOUTCOMES.112.965848>.
- [37] Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015;36:1012–22. <http://dx.doi.org/10.1093/eurheartj/ehv043>.
- [38] Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013;34:3035–87. <http://dx.doi.org/10.1093/eurheartj/ehu108>.
- [39] Thompson S, Kaptoge S, White I, Wood A, Perry P, Danesh J; Emerging Risk Factors Collaboration. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. *Int J Epidemiol* 2010;39:1345–59. <http://dx.doi.org/10.1093/ije/dyq063>.
- [40] Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM; Emerging Risk Factors Collaboration. Assessing risk prediction models using individual participant data from multiple studies. *Am J Epidemiol* 2014;179:621–32. <http://dx.doi.org/10.1093/aje/kwt298>.

## APPENDIX 1

### EAS FAMILIAL HYPERCHOLESTEROLAEMIA STUDIES COLLABORATION (EAS FHSC) PROTOCOL



**THE EUROPEAN ATHEROSCLEROSIS SOCIETY  
FAMILIAL HYPERCHOLESTEROLAEMIA  
STUDIES COLLABORATION  
[EAS FHSC]**

**STUDY PROTOCOL**

Version: June, 2016



**THE EUROPEAN ATHEROSCLEROSIS SOCIETY**  
**FAMILIAL HYPERCHOLESTEROLAEMIA STUDIES COLLABORATION**

– EAS FHSC –

---

## **STUDY DESIGN**

International registry of individuals with familial hypercholesterolaemia (FH). The EAS FHSC registry consists of a consortium of worldwide FH cohorts, registries, databases and data collections with access to information on individuals with a clinical and/or genetic diagnosis of homozygous (HoFH) and/or heterozygous (HeFH) FH.

**Scope:** multinational, multicentre; worldwide scope.

**Data:** cross-sectional and longitudinal (retrospective and prospective).

### **Selection of participants to be included in the registry:**

- Inclusion criteria:
  - Individuals with a diagnosis of heterozygous or homozygous FH.  
 Diagnosis: clinical and/or genetic.  
 Also including positive clinical diagnosis with negative genetic test and vice versa.  
 In case of clinical diagnosis:
    - Criteria used: Dutch Lipid Clinics Network, MedPed, Simon-Broome, Japanese criteria, or other to be specified.
    - Categories of possible, probable and confirmed FH.
  - Relatives of index cases without a diagnosis of FH where screening (cascade or other) is carried out.
- Exclusion criteria:
  - Secondary causes of dyslipidaemia (e.g. untreated hypothyroidism, cholestasis, nephrotic syndrome).
  - Where data collation does not conform to the local or country wide standards for anonymised data.

**Duration:** intended to be run for the long-term in order to increase the follow-up of patients already included, to include new individuals diagnosed with FH over time, to bring new cohorts to the registry, and to take into account contemporary changes in clinical practice, so that the findings remain relevant. The project is expected to evolve over time as will be further developed and expanded. The process is expected to be dynamic as we aim to continuously employ the best data sharing strategies and optimise our operational protocols based on the experience of the consortium, number of participants included, the results from the first wave of data collated, evolving aims, resources available and feedback from those utilising the data and the feedback from the wider medical community.

## **STUDY OBJECTIVES**

The mission statement of the EAS FHSC aims to empower the medical and global community to seek changes in their respective countries or organizations regarding how FH is detected and managed and the clinical consequences thereof, with a view to promoting early diagnosis and more effective treatment of FH.

The general aims of the EAS FHSC are:

- To establish a global registry of FH with a view to gaining an in-depth understanding of the contemporary burden of both HoFH and HeFH: patient management, treatments, impediments, long-term risks, impact of patient-specific and societal factors, gene–drug interactions and the role of screening.
- To disseminate the information gained from the above-mentioned activities to an international audience including physicians and other healthcare professionals, as well as patient organizations, with a view to sensitising them to the contemporary burden of FH, encouraging open discussion on the management of FH patients, promoting a uniform, evidence-based standard of care, and encouraging them to contribute actively to research.

### **Objectives**

1. To establish an international, standardised registry of patients with FH by bringing together regional, national and international cohorts and registries with access to patients with FH, in order to maximise the potential exploitation of the data and generate large scale, robust information to accurately and reliably investigate (i) the burden of both HoFH and HeFH, (ii) how it is detected and managed, (iii) the clinical consequences of current practice on delivery of care and outcomes, and (iv) the determinants influencing optimal management and LDL-C target attainment in FH. This will include but will not be limited to the following:

#### 1.1. General and cross-sectional analyses:

- How FH patients are detected, comparison of different proposed diagnostic criteria, whether current screening strategies for FH are adequate and, if not, what could be done differently to maximise coverage.
- How patients are managed, treatments offered/advised, how their efficacy is monitored.
- What proportion of FH patients meet the targets (e.g. LDL-C goals, patients receiving therapy), the impediments in attaining LDL-C goals, the role played by societal factors (such as access to healthcare in different settings and the availability of specialist advice) in enabling treatment to achieve LDL-C goal, the influence of gene–drug interactions in attaining LDL-C goals.
- The impact of patient-specific factors, socio-economic factors and treatment-related factors on LDL-C goal attainment.
- Potential variations depending on different geographic settings as a result of factors such as population genetics, health care delivery systems and other patient-, socio-economic- or treatment-related factors.
- Where possible, evidence for economic evaluation of different screening strategies and of interventions will be addressed.

1.2. Risk stratification beyond LDL-C levels, e.g. by genotype (to establish the value of incorporating genetic data into the clinical diagnosis of FH) or lipoprotein(a) levels.



- 1.3. Analysis of risk/outcomes: Long-term risk of outcomes in patients with FH (including, where possible, estimates of the years lost due to FH), with a special focus on the following end-points:
- Primary end-point
    - The composite of Cardiovascular Disease Events (fatal and non-fatal).
    - Cardiovascular mortality.
    - All-cause mortality.
  - Secondary end-points:
    - Each component of the Cardiovascular Disease Events end-point separately.
    - Aortic valve and supraaortic disease.
    - Statin intolerance (clinical, biochemical).
    - New onset of diabetes.
    - Cancer diseases.
    - Pregnancy outcome in female patients with FH.
  - The impact of patient-specific factors, socio-economic factors and treatment-related factors on outcomes.

The following definitions shall apply: (i) Cardiovascular Disease Events: the composite of fatal and non-fatal coronary heart disease/acute coronary syndrome/myocardial infarction, cardiac sudden death, fatal and non-fatal stroke, transient ischemic attack, peripheral vascular disease, and revascularization (percutaneous or surgical); (ii) Aortic valve and supraaortic disease: confirmed by any imaging test; (iii) Statin intolerance (clinical and/or biochemical): defined according to the EAS consensus panel (*Eur Heart J* 2015;36:1012-22); (iv) New onset of diabetes mellitus: fasting glycaemia >126 mg/dL at least in two separately occasions, glycosylated haemoglobin  $\geq$ 6.5%, and/or patient receiving a new prescription of an antidiabetic drug (*Eur Heart J* 2013;34:3035-87). (v) Pregnancy outcomes refer to maternal, obstetric and neonatal outcomes.

**2.** To develop and implement a novel bespoke electronic platform and FH data warehouse for data sharing, cleaning, harmonisation and analysis for patients with FH to support the FH registry. It will allow the collation of retrospective and prospective data from multiple sources and different formats, and will support the management of a large amount of data, critical to ensure sustainability.

**3.** To disseminate the information gained from the FH registry to an international audience including physicians, other healthcare professionals, policy-makers and patients organizations. To sensitise the different stakeholders involved in FH care to the contemporary burden of FH, encourage open discussion on the management of FH patients and their families, promote a uniform evidence-based standard of care, and encourage those involved in FH care to contribute actively to research.

**4.** To consolidate a network of investigators interested in FH through which collaborative research and networking on FH can be conducted on a large scale.

## **DATA SHARING**

We will develop a system whereby the data sets will be transferred to and collected by the Coordinating Centre through a secure web platform. Data sharing plans involve instructions to the lead investigators for



data to be transferred and data to be collected, updated with feedback for the individual investigators providing the data. For each cohort/data set a two-stage approach will be followed: the first one comprises the collation of the cross-sectional and retrospective data readily available; the second stage will involve integration of longitudinal, prospective records (including follow-up data).

In order for these investigators' to provide reliable data for inclusion, a set of minimum predefined quality and operational criteria must be fulfilled:

- The data must be in electronic format;
- The amount of data shared should be considered enough to add relevant information to the registry;
- The data must have been collected rigorously following a standardised well-designed protocol; inclusion and exclusion criteria must be well defined; FH must be well defined according to accepted criteria and not rely only on self-reported history of FH; any measurements recorded must have been done with validated and standardised methods and devices; standardised definitions should have been used; the participants included should be representative of the target population;
- The parameters recorded must include at least the minimum set of data (core information) specified below;
- Local ethical and security aspects must be in place;
- The data sharing agreement must be signed prior to any data transfer.

A detailed data request form for providing anonymised data will be sent to the investigators contributing to the registry for them to provide data on individuals with FH and their relatives where available. A minimum set of data (core data) will be required to be included in the registry, comprising:

- How patients are being managed (e.g. cascade screening, availability of genetic testing);
- Characteristics of the clinics providing the data (e.g. number of physician and nurses, specialised clinic or general physicians, public or private clinic, etc.);
- General and demographic information;
- Familial and personal cardiovascular history; other cardiovascular risk factors;
- FH diagnostic criteria;
- Where genetic tests are available, these genetic data will form part of the core data requested.
- Lipid-lowering medication with doses;
- Laboratory lipid profile;
- Data on outcomes if follow-up exists (retrospective or prospective);
- In the case of HoFH, data about LDL apheresis will also be collected.


Additional data to be collected where available include a number of other parameters of interest such as more detailed information on comorbidities, other medications and laboratory results, tests such as electrocardiography, echocardiography, calcium coronary scores, angiography, etc. (annex 1).

Where possible, standardised definitions will be used and free text avoided. We will encourage that investigators provide updates of shared data sets within a reasonable timeframe.

We will develop data quality assurance strategy which will include, for example: measurement of data consistency and instituting a standard method for analysing the reasons for, and impact of, any data inconsistencies. We will continually improve the quality of the data with a data quality assurance system.

Individual investigators from each local site will contribute to the FH registry through the National Lead Investigators/Country-leads (NLI/CLs) for each region or country. These NLI/CLs will transfer and upload the data to the Coordinating Centre through a bespoke secure web portal. See next figure.

Where possible, depending on the funding and resources available at each time, the EAS FHSC will try to provide the lead investigators with a certain amount of funds to help in the management of data with the purpose of data sharing.



## **DATA MANAGEMENT**

The preliminary data shared will be checked for consistency and accuracy by at least 2 independent investigators of the Coordinating Centre (scientific coordinator, data manager), and any discrepancies will be resolved by raising queries with the individual investigators. The Coordinating Centre, supported by a technical team, will develop cutting edge and artificially intelligent routines incorporating machine learning for automated data cleaning, harmonising and make the data uniform and compatible. Various suitable well-defined data models will be designed into which collected and cleaned data will be loaded. After ensuring satisfactory data quality from all registries (contributors), the information will be saved into a central database to be held securely on a server at the Coordinating Centre (Imperial College London, UK) in strict adherence with all data safety protocols and regulatory requirements i.e. Society for Clinical Data Management (SCDM), Clinical Data Interchange Standards Consortium (CDISC), Study Data Tabulation Model Implementation Guide for Human Clinical Trials (SDTMIG) and the Clinical Data Acquisition Standards Harmonization (CDASH) standards. A bespoke Data Warehouse hosted at the Coordinating Centre will be developed to consolidate heterogeneous data from multiple sources and formats through appropriate smart algorithms. A central, well-organised, robust, secure, compliant “data warehouse” with different well-defined data models hosted by the Coordinating Centre will be key for multiple reporting and analysis use-



cases, allowing researchers and stakeholders immediate access to processed, clinically relevant rich information.

During the course of the project various tools will be developed to support, improve, standardise and automate the Data Management. These tools are mainly:

- **Process Workflow:** The Data Management involves various steps and a uniquely focussed advanced workflow will be designed for automating the whole process. The workflow will streamline the entire process all the way from designing data models, data collection, data validation, data harmonization, data transformation and data analysis and reporting. The workflow itself will be a cloud based solution hosted as a software-as-a-service (SaaS) application to meet demanding requirements of the global project.
- **Data Monitoring Application:** The Data Management monitoring application will be designed and developed to complement the workflow to ensure homogenisation of the data to meet all regulatory requirements and will be updated regularly to ensure adherence to contemporary local and global regulatory standards. The monitoring application will help administrators to be involved at all stages of data management right from inception to completion. The monitoring of the various stages of data management will ensure the quality standards are maintained and any deviations from protocols are immediately reported and rectified. Due to the heterogeneous nature of data collected from multiple sources; it will be critical for various data management stages of the workflow to be assessed for quality at regular intervals during whole project including, database designing, data validation, discrepancy management, medical coding, data extraction, and database locking.
- **Process Logging System:** The data will go through various stages during the Data Management cycle. It is therefore important to have a system which logs changes made to the collected data during various stages i.e. data validation, data harmonisation, data standardisation and data transformation. The logging system will help administrators in reverting data to the original state if there are conflicts or errors. The logging system will be essential for auditing the whole process and to improve the Data Management according to the requirements and suggestions of stakeholders. In the absence of a proper logging system there is a potential to introduce un-detectable errors and merge sub-standard data with the master data for any global project. The process logging system will also bring transparency, assurance and instil confidence to national and international data contributors.

## **PLATFORM AND DATA WAREHOUSE**

We will develop a central database that would consolidate subject-oriented, time-variant and non-volatile data from multiple sources into a robust large scale FH Data Warehouse (FHDW). The FHDW will provide through novel informatics the capacity for retrospective and ongoing prospective data pooling, harmonisation and analysis. The integration, validation, processing, and exploration of complex data is a technical challenge for clinical researchers and a major rate limiting step to clinical FH research projects. Through the bespoke data architecture and platform which we will develop we will support: secure data harvesting from multiple global repositories/databases/file systems; data cleaning, validation, quality control and merging into a Data Warehouse hosted by the Coordinating Centre at Imperial College London, UK, in strict adherence with all data safety protocols and regulatory requirements. The standardized central data will support intelligent data analysis. The FHDW is envisioned as the “master” repository for FH specific health care data that can integrate disparate sources of data on the same individuals for instance at later time points, in order to support the evolving information trail and analytical requirements of stakeholders involved in the management, evaluation and care of the FH patients. Once built, the FHDW will serve as a key resource


for implementing the various outputs e.g. quality measurement, quality improvement, analyse trends over time. Its goal is to make isolated data easily accessible, reliable, consistent, and secure to support informed planning, decision-making, and communication. The aggregated FH data will be the principal source for identifying valid, novel, potentially useful, and ultimately understandable patterns in large scale complex data across multiple countries, providing both power and precision, thus facilitating “Knowledge Discovery” to tackle the population burden of FH.

The FHDW will incorporate the data backup and recovery policies for minimal downtime of the platform. These policies will be flexible and adaptable to usage and demands of the platform. Main aspects of backup policies of the raw data (shared by each NLI/CL) and the master copy of the consolidated data are:

- Full backups of FH data will be performed weekly. Full backups will be retained for 3 months before being overwritten;
- Incremental backups of the FH data will be performed daily. Incremental backups are retained for 1 month;
- Backups will be run during minimal load time;
- Backups are stored in secure location/s different from master copy. A limited number of authorised personnel will have access to the backup data;
- Data will be available for restoring within a few minutes of a backup job completing;
- Data will be available during the retention policy of each backup job i.e. 3 months;
- The potential data loss during a working day will be avoided by utilizing incremental backup and process logging system.

The replication of master data into multiple copies will be stored on independent and remote servers.

The overall architecture of the FHDW and its corresponding platform is shown in the figure below. The FHDW will be a complete platform supporting various research activities and thus will be composed of the following components:





1. **Web Portal for Data Collection:** The secure web portal will be developed as a means for data coordination. National Lead Investigators/Country-leads will be asked to upload data via portal for transparency and auditing purposes.
2. **Data Validation:** Cutting edge open source technologies will be used to Extract, Transform and Load (ETL) data onto the Global Data Warehouse. The extracted data will be of the highest quality, structurally valid, and contextually rich.
3. **Data Collation:** The validated retrospective as well as prospective patient data (follow-up of patients) from different global sources will be merged within the central database.
4. **Data Analysis Tools:** Widely accepted data analysis, data mining and reporting tools will be employed on the merged data to support an arbitrary number of queries and research questions.
5. **Web Portal for Reporting:** A secure web portal will also be developed to generate various reports for stakeholders. The purpose of these reports is to highlight healthcare trends, limitations and improvement scope; only extractable from the merged central database.
6. **Data Storage:** Raw data will be stored in unstructured database (NoSQL) specific to contributors and merged data will be stored in the structured format in relational database with technical capacity to handle a large number of participants with lifetime events history.
7. **Privacy Tool:** To protect patient privacy, only anonymised data will be collected and aggregated, and a Global Unique Identifier (GUID) will be assigned to each patient's data. The GUID approach enables researchers to follow patients over time and across different events, studies and countries.
8. **Data Management Workflow:** An advanced workflow will be designed for automating the whole process of Data Management. The workflow will streamline the entire process all the way from designing data models, data collection, data validation, data harmonization, data transformation and data analysis and reporting.
9. **Workflow Monitoring:** The monitoring application will help administrators to be involved in all stages of data management right from inception to completion; thus ensuring the quality standards are maintained and any deviations from protocols are immediately reported. The system will make use of existing standards for wider acceptance and interoperability.
10. **Logging Tool:** The logging tool will log changes made to the collected data during various stages. The logging tool will help administrators to improve the Data Management process and in reverting data to the original state if there are conflicts or errors. The process logging system will also bring transparency for the confidence of national and international data contributors.

Traditional data warehouses require metadata or a common vocabulary, which is already well defined and used in many other domains, such as banking or finance. The FHDW aims to define FH specific domain metadata in a similar fashion, based on common vocabularies and related standards in medicine. Furthermore, the elaborate structural meta-information will be used to actively support the user in tasks that usually require significant IT knowledge, such as defining complex search queries or data quality constraints, or applying advanced data visualization algorithms to the data. The proposed warehouse supports the domain expert through the whole process of knowledge discovery from data integration to exploration.

#### **Data Extract, Transform and Load (ETL)**

Once the data is safely transferred to the Coordinating Centre through the EAS FHSC web portal and after ensuring satisfactory data quality, the information will be harmonised into the central FHDW. The FHDW will consolidate heterogeneous data from multiple sites through bespoke smart algorithms. The heterogeneity of source data models, data navigation, integrity, unit compatibility and attributes to uniform data definition language (DDL) are resolved by Extract, Transform and Load (ETL). The machine learning and expert system


based declarative rules will ensure highest quality, structurally valid, and contextually rich data. The FHDW will manage two types of data: core datasets and additional datasets, accommodating future requirements. The raw source data (including additional datasets) will be stored in an unstructured database (NoSQL) and merged data (core dataset) will be stored in the relational database with technical capacity to handle Big Data with lifetime events history. Internal partitioning of data in data marts will support an arbitrary number of queries and research questions; conceptual cubes and dimensions will be employed for complicated multifaceted queries. The research subject based data marts and cubes will optimize analysis, reporting and visualization of large global data. Data acquisition and workflow merging will be managed and monitored by an interactive dashboard to maintain the status of all key steps.

Data servers physically hosted by ICL are encrypted to industry standards utilizing public–private key infrastructure. A Global Unique Identifier (GUID) will be assigned to each subject enabling investigators to follow their own subjects over time.

The resource makes use of existing standards for wider user acceptance, technical interoperability and scalability. Regular surveys of the users' (lead investigators') experience will capture their expectations and obtain key suggestions and feedback, allowing appropriate adaptation and improvements of the user/resource interface, enhancing end-user experience for ease-of-use and efficient data management, allowing the resource to properly grow and evolve.

#### Multi Stage Data Storage for enhanced Security

The nature of data and research requires robust architecture for the data storage. The data will be stored physically on servers hosted by ICL with different access controls. The main architecture for the data collection is shown in the figure below:



- **Data Extraction:** National Lead Investigators/Country-leads will extract data from their local data storage systems taking into consideration of the specific requirements/limitations locally. The FHDW technical team will provide reasonable support to lead Investigators to carry out this task.
- **Web Portal for Data Collection:** National Lead Investigators/Country-leads will use the secure Web Portal to upload his/her copy of extracted data. The Web Portal communication will be based on Transport Layer Security (TLS 1.2) and 128 bits Advanced Encryption Standard (AES 128).
- **Temporary Data Server for Data Storage:** The Web Portal will upload the data to the temporary server in the partitions specific to the corresponding National Lead Investigator/Country-lead. An event will be generated for the data to be moved to a more secure place once the data upload is complete. Once the data is copied to the next stage the data will be removed from Temporary Data Server. This is in line with standard practice.
- **Intermediary Data Server for Data Harmonisation:** The uploaded data is immediately moved to the secure data server which has no public access. This data server contains the data 'as is' and is used as a holding area to determine whether data meets quality and protocol requirements. Entry into this layer



- should be through a number of ‘data quality’ gateways to ensure that erroneous or missing data is rejected or handled appropriately.
- **Secure Data Server for Data Warehouse:** The most secure data server will host the FHDW, with no external and public access. The communication with FHDW will only be via a secure messaging service and the Secure Data Server will be configured to read and write messages from/to the messaging service. This will contain a single table and a number of reference tables. Each related table may reference a number of additional tables. Data structured in this manner will be used to produce/populate Online Analytical Processing (OLAP) style cubes.
  - **Application Server for Data Analysis and Reports:** The application server will have various executable tools and scripts with artificial intelligence. The application server will request from the FHDW a subset of data via secure messaging service for relevant data. Once the requested data is received, it will be analysed and only analysis results and reports will be saved on the application server; the requested data will be discarded and deleted after successful processing.

## **ANALYSIS PLAN**

Where possible and after ensuring consistency and compatibility of the information and description of the variables, the data from different providers will be merged and analysed at an individual level as a composite dataset. Where this is not possible, analyses will be carried out at a country/provider level, by analysing each dataset individually and then pooling the results together.

The harmonised registry will allow us to conduct different types of analyses, such as verifying previous published findings with greater power and precision, conducting alternative analyses of the same data, novel new analyses, cross-cohorts comparisons, meta-analyses, analysing unpublished data (not previously conducted due to low sample size within each separate dataset), conducting exploratory analyses to generate new research hypothesis, etc.

A number of research questions will be addressed, such as those shown in the table below:

1	How FH patients are detected, comparison of different proposed diagnostic criteria, whether current screening strategies for FH are adequate and, if not, what could be done differently to maximise coverage.
2	How patients are managed, treatments offered/advised, how their efficacy is monitored.
3	What proportion of FH patients meet the targets (e.g. LDL-C goals, patients receiving therapy), the impediments in attaining LDL-C goals, the role played by societal factors (such as access to healthcare in different settings and the availability of specialist advice) in enabling treatment to achieve LDL-C goal, the influence of gene–drug interactions in attaining LDL-C goals.
4	<p>Long-term risk of outcomes in patients with FH (including, where possible, estimates of the years lost due to FH), with a special focus on the following end-points:</p> <ul style="list-style-type: none"> <li>▪ Primary end-point 1: the composite of Cardiovascular Disease Events (fatal and non-fatal).</li> <li>▪ Primary end-point 2: Cardiovascular mortality.</li> <li>▪ Primary end-point 3: All-cause mortality.</li> <li>▪ Secondary end-points: <ul style="list-style-type: none"> <li>- Each component of the Cardiovascular Disease Events end-point separately.</li> <li>- Aortic valve and supralvalvular disease.</li> <li>- Statin intolerance (clinical, biochemical).</li> <li>- New onset of diabetes.</li> <li>- Cancer diseases.</li> <li>- Pregnancy outcome in female patients with FH.</li> </ul> </li> </ul>



5	To establish the value of incorporating genetic data and other factors (e.g. lipoprotein[a]) into the clinical diagnosis of FH and estimation of the risk of outcomes.
6	The impact of patient-specific factors, socio-economic factors and treatment-related factors on LDL-C goal attainment and cardiovascular risk.
7	Potential variations depending on different geographic settings as a result of factors such as population genetics, health care delivery systems and other patient-, socio-economic- or treatment-related factors.
8	Where possible, evidence for economic evaluation of different screening strategies and of interventions will be addressed.

Standard validated statistical procedures and models for observational studies and weighted meta-analyses (individual participant data meta-analysis where possible; meta-analysis of aggregated data alternatively) will be applied. Statistical methods described in studies such as the Emerging Risk Factors Collaboration [Thompson S et al, *Int J Epidemiol* 2010;39(5):1345-59; Pennells L et al, *Am J Epidemiol* 2014;179(5):621-32] or the Non-Communicable Diseases Risk Factor Collaboration [NCD-RisC, *Lancet* 2016;387:1513-30] will be used where appropriate. After exploratory analyses with description of the variables of interest, cross-sectional analyses and correlates will be performed. Comparisons of continuous parameters will be done with parametric and non-parametric tests as appropriate and categorical variables using Chi-squared test. We will estimate exposure–outcome associations (unadjusted and adjusted) and epidemiological interactions using standard regression models. Risk prediction models using measures of discrimination (concordance index [C-index], discrimination measure [D-measure]) and reclassification (net reclassification index [NRI]) are intended to be performed. Cox proportional hazards regression models stratified by certain variables of interest (e.g. by gender, country, etc.) and Kaplan–Meier estimates of survival will be generated where time-to-event data is available. Measures of heterogeneity and risk of bias (e.g. regression dilution over time) will be applied.

We will account for different variables of interest, carry out appropriate adjustments systematically, consider key subgroups and correct for differences in definitions. Where feasible, reliable, and data available we will also try to roughly approximate the prevalence of FH by extrapolating the data to the general population. The different sources of incoming data will also help assess potential variations depending on different geographic settings, including factors such as population genetics, healthcare delivery systems and other patient-, socio-economic- or treatment-related factors.

Particular emphasis will be placed on exploring differences between key subgroups including but not limited to the following: HoFH and HeFH; different genetic subtypes of FH (e.g. broadly whether due to mutations in the LDL-receptor, ApoB, PCSK9 or LDL-receptor adaptor protein pathways); diagnosis based on different diagnostic criteria; clinical vs. genetic diagnosis; FH treated by a generalist vs. specialist; FH with pre-existing CVD vs. those without; FH with a family history of premature CVD vs. those without; FH individuals who attain LDL-C targets on standard treatments vs. those who do not; geographical region; gender and ethnicity; age at baseline; age at first treatment initiation.

The different sources of incoming data will help us assess potential variations depending on different geographic settings, including factors such as population genetics, health care delivery systems and other patient-, socio-economic- or treatment-related factors.

Following a “database-query” model, investigators involved in the registry will be able to submit research questions they would like to evaluate through the Coordinating Centre; if the request is deemed to be



scientifically relevant by the Executive Committee and considered feasible by the Coordinating Centre, the latter will construct and run the analyses and return the results to the requester.

## **STUDY OPERATIONAL/GOVERNANCE STRUCTURE**

Due to the complexity and scale of the project, to ensure the smooth operation within the wide EAS FHSC global network, the EAS FHSC is supported by an Executive and a Steering Committees, a number of National Lead Investigators/Country-leads and a Coordinating Centre.

- **Executive Committee (EC):** the EC consists of a panel of experts in the field of FH led by Prof. Kausik K. Ray (Imperial College London, UK) and it represents the academic leadership of the EAS FHSC. It is constituted by the following members:
  - Prof. Kausik K. Ray (UK)
  - Dr. Handrean Soran (UK)
  - Prof. John J. Kastelein (The Netherlands)
  - Prof. G. Kees Hovingh (The Netherlands)
  - Prof. Pedro Mata (Spain)
  - Prof. Gerald F. Watts (Australia)
  - Prof. Frederick Raal (South Africa)
  - Prof. Raul Santos (Brazil)
  - Prof. Alberico L. Catapano (Italy)
  - Dr. Tomas Freiburger (Czech Republic)

The EC represents the core group for overarching management decisions, driving the collaboration, obtaining support and funding to ensure sustainability. The EC will evaluate all proposals for research, data mining, and expansion of the EAS FHSC. The EC are expected to play an active role in raising awareness nationally and internationally for the EAS FHSC and disseminating data that arises from this collaboration. The EC may delegate day-to-day tasks to the Coordinating Centre such as the day-to-day running and decisions related to data collation, harmonisation and pooling. The EC will typically meet once per year; these meetings will be organised by the Coordinating Centre. More frequent interactions will be by teleconference, as necessary.

- **Steering Committee (SC):** the SC represents the advisory committee to provide guidance on the EAS FHSC project development. It consists of all those investigators/stakeholders/experts, usually appointed as EAS FHSC National Lead Investigators/Country-leads for their respective countries/regions.
- **National Lead Investigators/Country-leads:** lead investigators act as a national leader for the EAS FHSC within their respective countries or regions; as such they coordinate and are responsible for the identification and collaboration from the individual sites, promote participation of other national physicians and researchers in the collaboration, liaise with relevant societies and patient organizations, obtain appropriate local approvals and permissions as required, and gather the data from the respective region/country to be transferred to the Coordinating Centre.
- **Coordinating Centre:** The Coordinating Centre for the FH registry is based at the School of Public Health, Imperial College London, UK. It will act as a nodal point for data collation and management, standardisation, consolidation, analyses and queries, and will communicate, support and coordinate the activity of the investigators involved. The Coordinating Centre will ensure the availability and updating



of various computational tools needed to collate, manage and share the data and will make use of analytical partners (e.g. informatics, biostatistics) to ensure the accurate generation of results.

## **ETHICS, SECURITY AND REGULATORY CONSIDERATIONS**

- Major principles guiding the present project development include the added scientific and social value, rigorous adherence to local ethical standards, protection of patients' data privacy and confidentiality, responsible sharing and use of the data, transparency in data management, and creating a secure workspace. This project and related research will be conducted in accordance with the principles of the Declaration of Helsinki (World Medical Association), EU Good Clinical Practice (GCP) and the Committee on Bioethics of the Council of Europe (DH-BIO).
- If required, approval from the corresponding ethical and/or research committees will be requested by the investigators to collect, transfer and share the data. Where needed, informed consent from participants for his/her data to be shared and included in the registry will be requested at the local level by the corresponding investigator. These actions will be coordinated by and will be the responsibility of the local sites/investigators. Requirements in this respect will depend upon the respective institutional/country policies and regulations.
- Data sharing agreements will be executed between the lead investigator sharing the data and the Coordinating Centre as the recipient of the data, specifying, amongst others, how the data are shared; under what conditions; data and results ownerships; recognition and acknowledgment of the work and intellectual contributions from the different parts according to their involvement; and restrictions on using the data for purposes other than those intended for the EAS FHSC project development (annex).
- The analyses will be performed according to rigorous plans, making use of scientific, standardized and validated analytical methods, and carried out by investigators having a skill level appropriate for the tasks assigned to them.
- Disclosures of conflicts of interests will be requested from all investigators involved in any report or publication.
- The investigators and the Coordinating Centre will use all reasonable safeguards in connection with any transfer, communication or remote access connectivity involving the data. A secure web portal will be developed as a means of data entry/coordination and controlled environment. Lead investigators will upload data via the portal for transparency and auditing purposes.
- Only de-identified, pseudo-anonymised data will be collected, and removal of evident identifiers such as names, health numbers, addresses, etc., replacement of dates with time intervals where possible, and categorization of characteristics such as ethnicity, education and others, will be carried out. Certain data such as age, gender or geographical location (e.g. country/region, rural/urban) will be requested as they are needed to maintain scientific value and utility of the present registry; appropriate judgement to protect participants' privacy and prevent identification will be done in these cases.
- The data shared will not be made publicly available, but limited to the outputs from the present project centralized at the Coordinating Centre. The combined data at the Coordinating Centre will not be checked against other external databases, thus preventing re-identification of participants. Information will not be available nor downloadable for any other part apart from specific scientific proposals agreed with steering group and conducted through the Coordinating Centre; it will not be disclosed/transferred to third parties; nor used for commercial purposes, although the outputs of the work will undoubtedly have implications for translational research and use of novel therapies for the pharmaceutical industry.

Clinical data will be handled in compliance with various ethical standards. Collated patient details will be collected in multi-stage infrastructure as discussed earlier. The project partners will upload the data securely on the intermediary storage server through a proper SSL configuration. Access to the data sharing platform is encrypted using Transport Layer Security (TLS 1.2) and 128 bits Advanced Encryption Standard (AES 128). Uploaded data will be transferred to another secure server and will be stored in a password-protected, secure database for instance with no public access. The database will be housed in an access-controlled server room, hosted by the Imperial College Information and Communications Technology department. The database will be encrypted using the standard encryption methods, and will be physically stored across hundreds of disks in a storage area network – this reduces the possibility for needing to reconstruct the database should a drive be lost. The database will have no public access and will be configured to be accessed from approved terminals/computers via firewall configurations.

The stored data will always incorporate the following components, security policies and procedures: authorization, authentication, availability, confidentiality, data integrity and non-repudiation. The methods available for authorization or access controls include single sign-on databases or lists assigning rights and privileges of users to access certain resources, automatic account logoff after a specified period of inactivity to prevent access by invalid users, and physical access controls.

Access to the database will be restricted to named individuals in the Imperial College London project team, with read/write access to data elements defined as required for their role. Access will be further restricted to specific computers on the Imperial College network by firewall configuration. The fool-proof storage mechanism will result in secured storage, manipulation, analysis and reporting of the data. The anonymised data securely held will only be shared according to the terms of consent under the data sharing agreement. The data storage and handling will be compliant with European Data Protection Act and local Data Protection Officers will be consulted in case of any doubt and ambiguity.

**ANNEX 1 – POTENTIAL VARIABLES OF INTEREST FOR THE EAS FHSC REGISTRY**

Shown as a guidance. See corresponding section in the text for explanation.

General	Demographics	Familial Hypercholesterolaemia	Clinical history
<ul style="list-style-type: none"> <li>- Patient ID (code)</li> <li>- Country</li> <li>- Date of birth: month/year</li> <li>- Date study entry: month/year</li> </ul>	<ul style="list-style-type: none"> <li>- Age</li> <li>- Gender</li> <li>- Ethnicity</li> <li>- Occupation</li> <li>- Education level</li> <li>- Geographical area: rural/urban</li> </ul>	<ul style="list-style-type: none"> <li>- Date of diagnosis</li> <li>- Age at diagnosis</li> <li>- FH type: homozygous/heterozygous</li> <li>- Clinical criteria used for diagnosis: DLCN/MedPed/Simon-Broome/Japanese FH criteria/other (specify)</li> <li>- Clinical criteria score</li> <li>- Clinical criteria diagnosis: no diagnosis/possible/probable/confirmed</li> <li>- Consanguinity: yes/no</li> <li>- Index case: yes/no</li> <li>- Availability of family tree: yes/no</li> <li>- Family tree code</li> </ul>	<ul style="list-style-type: none"> <li>- Hypertension: yes/no</li> <li>- Diabetes: type 1/type 2/other/no</li> <li>- Hypertriglyceridaemia: yes/no</li> <li>- Smoker: current/former/never</li> <li>- Pack-years smoking: number of cigarettes smoked per day divided by 20 and then multiplied by the number of years smoked</li> <li>- Alcohol</li> <li>- Physical activity</li> <li>- CAD: yes/no</li> <li>- Premature CAD: yes/no [premature: male &lt;55y, woman &lt;60y]</li> <li>- MI: yes/no</li> <li>- Coronary revascularization: yes/no</li> <li>- Cerebral vascular disease: yes/no</li> <li>- Peripheral artery disease: yes/no</li> <li>- Aortic valve disease: yes/no</li> <li>- Supravalvular disease: yes/no</li> <li>- Premature non-coronary vascular disease: yes/no [premature: male &lt;55y, woman &lt;60y]</li> <li>- CKD: yes/no</li> <li>- CKD stage: KDOQI</li> <li>- Hepatic steatosis (suggested by US): yes/no</li> <li>- Achilles tendon lesions: tendinitis/injury-surgery/no</li> </ul>
Family history	Examination	Genetic study	
<ul style="list-style-type: none"> <li>- Family history of FH: yes/no</li> <li>- Family history of hypercholesterolaemia: yes/no</li> <li>- Family history of CAD: yes/no</li> <li>- Family history of other CVD (stroke, PAD): yes/no</li> <li>- 1st degree relative premature CAD: yes/no [premature: male &lt;55y, woman &lt;60y]</li> </ul>	<ul style="list-style-type: none"> <li>- Weight: kg</li> <li>- Height: cm</li> <li>- BMI: kg/m<sup>2</sup></li> <li>- Waist circumference: cm</li> <li>- Corneal arcus: yes/no</li> <li>- Xanthomas: yes/no</li> <li>- Xanthelasma: yes/no</li> <li>- Systolic BP: mmHg</li> <li>- Diastolic BP: mmHg</li> <li>- Heart rate: bpm</li> </ul>	<ul style="list-style-type: none"> <li>- Genetic study: positive/negative/not done</li> <li>- FH defect: heterozygous/compound heterozygous/homozygous/ARH</li> <li>- Mutation gene: LDLR/ApoB/PCSK9/LDLRAP1/Unknown</li> <li>- Mutation type: stop/insertion/deletion/ etc.</li> <li>- Mutation result: defective allele/null allele</li> <li>- Residual LDLR activity: %/unknown</li> <li>- Mutation: nomenclature, name</li> </ul>	



Lipid-lowering therapy	Lipoprotein apheresis (LA)	Lab profile (fasting)	Additional tests
<ul style="list-style-type: none"> <li>- Lipid-lowering therapy: no/monotherapy/combination therapy</li> <li>- Statin: yes/no</li> <li>- Date starting statin: month/year</li> <li>- Type of statin: simvastatin/pravastatin/lovastatin/fluvastatin/atorvastatin/rosuvastatin/pitavastatin</li> <li>- Dose of statin: mg/d</li> <li>- Statin intolerance: yes/no</li> <li>- Ezetimibe: yes/no</li> <li>- Fibrate: yes/no</li> <li>- Bile acid sequestrants: yes/no</li> <li>- N-3 fatty acids: yes/no</li> <li>- Niacin: yes/no</li> <li>- Sterols/stanols: yes/no</li> <li>- Lipoprotein apheresis: yes/no</li> <li>- PCSK9 inhibitor: yes/no</li> <li>- Lomitapide: yes/no</li> <li>- Mipomersen: yes/no</li> <li>- CEPT inhibitor: yes/no</li> <li>- Other: e.g. whether treatment has been continuous or intermittent, data/measurements of adherence to therapy, other (specify)</li> </ul>	<ul style="list-style-type: none"> <li>- LA: yes/no</li> <li>- Indication: homozygous FH/severe heterozygous FH/other (specify)</li> <li>- Date starting: month/year</li> <li>- Pre-LA lipid profile</li> <li>- Pre-LA lipid-lowering drug</li> <li>- Post-LA lipid profile</li> <li>- Method of apheresis</li> <li>- System used</li> <li>- Calculated volume</li> <li>- Anticoagulation during apheresis</li> <li>- Place apheresis performed: lipoprotein apheresis unit/renal department/haematology department/other (specify)</li> <li>- Via: native veins/AV fistula/AV shunt</li> <li>- Lines: central lines/other lines</li> <li>- Duration episode of apheresis</li> <li>- Frequency of apheresis</li> <li>- Complications: no/yes (specify)</li> </ul>	<ul style="list-style-type: none"> <li>- Total Cholesterol</li> <li>- LDL-C</li> <li>- HDL-C</li> <li>- Non-HDL-C</li> <li>- Triglycerides</li> <li>- Apolipoprotein A1</li> <li>- Apolipoprotein B</li> <li>- Lipoprotein (a)</li> <li>- Creatin kinase (CK)</li> <li>- Aspartate aminotransferase (AST)</li> <li>- Alanine aminotransferase (ALT)</li> <li>- C-reactive protein (CRP)</li> <li>- Glucose</li> <li>- Glycated haemoglobin (HbA1c)</li> <li>- Estimated glomerular filtration rate (eGFR): MDRD</li> <li>- Microalbuminuria</li> </ul>	<ul style="list-style-type: none"> <li>- ECG:           <ul style="list-style-type: none"> <li>▪ Rhythm: sinus rhythm/atrial fib/flutter/other</li> <li>▪ LVH: (Sokolow-Lyon)</li> <li>▪ Other disorder: specify</li> </ul> </li> <li>- Echocardiography:           <ul style="list-style-type: none"> <li>▪ LVEF: %</li> <li>▪ LV hypertrophy: yes/no</li> <li>▪ Septum: mm</li> <li>▪ Posterior wall: mm</li> <li>▪ LV mass index: g/m<sup>2</sup></li> <li>▪ Abnormal wall motion: yes/no</li> </ul> </li> <li>- Carotid Ultrasonography:           <ul style="list-style-type: none"> <li>▪ Carotid plaque: yes/no</li> <li>▪ Carotid (CCA) IMT: yes/no</li> <li>▪ Carotid atherosclerotic stenosis: %/no</li> </ul> </li> <li>- Liver Ultrasonography: Liver steatosis: yes/no</li> <li>- Renal arteries Ultrasonography: stenosis: yes/no</li> <li>- Lower extremity Ultrasonography: Stenosis: iliac/femoral/distal/multiple/no</li> <li>- Ankle-brachial index: Result</li> <li>- Coronary calcium score:           <ul style="list-style-type: none"> <li>▪ Method:</li> <li>▪ Score:</li> </ul> </li> <li>- Coronary angiography/revascularization:           <ul style="list-style-type: none"> <li>▪ Coronary angiography: no lesions/diffuse disease/focal stenosis</li> <li>▪ If stenosis: &lt;50%/≥50%/&gt;70%</li> <li>▪ Coronary arteries affected: none/LCA/LAD/LCx/RCA/several</li> <li>▪ PCI: yes/no</li> <li>▪ CAGB: yes/no</li> </ul> </li> <li>- Other test available: Describe. E.g. MRI, etc.</li> </ul>
<b>Other therapy</b> <ul style="list-style-type: none"> <li>- Antiplatelet: yes/no</li> <li>- ACEI: yes/no</li> <li>- ARB: yes/no</li> <li>- B-blocker: yes/no</li> <li>- CCB: yes/no</li> <li>- Other BP-lowering drug: yes/no</li> <li>- Oral glucose-lowering drug: yes/no</li> <li>- Insulin: yes/no</li> </ul>	<b>Follow-up</b> <ul style="list-style-type: none"> <li>- Date FH diagnosis</li> <li>- Date of enrollment</li> <li>- Date of first data collection</li> <li>- Date of subsequent follow-up visits</li> <li>- Date of event</li> <li>- Number of visits</li> <li>- Changes in medication</li> </ul>		

Outcomes / Events			
<ul style="list-style-type: none"> <li>- Date of event</li> <li>- Age at event</li> <li>- Cardiovascular event                             <ul style="list-style-type: none"> <li>• Acute coronary syndrome: fatal/non-fatal</li> <li>• Myocardial infarction: fatal/non-fatal</li> <li>• Sudden cardiac death</li> <li>• Stroke: fatal/non-fatal</li> <li>• Transient ischemic attack</li> <li>• Peripheral vascular disease</li> <li>• Revascularization: percutaneous/surgical</li> <li>• Heart failure</li> <li>• Aortic valve/supravalvular disease</li> </ul> </li> <li>- Death: Cause of death:                             <ul style="list-style-type: none"> <li>▪ CAD</li> <li>▪ Sudden cardiac death</li> <li>▪ Cerebrovascular disease: ischemic/haemorrhagic</li> <li>▪ Heart failure</li> <li>▪ Acute aortic syndrome</li> <li>▪ Cancer</li> <li>▪ Other (specify)</li> </ul> </li> <li>- Statin intolerance: clinical/biochemical/both</li> <li>- New onset of diabetes</li> <li>- Cancer disease: type</li> <li>- Pregnancy outcomes:                             <ul style="list-style-type: none"> <li>▪ Maternal</li> <li>▪ Obstetric</li> <li>▪ Neonatal</li> </ul> </li> </ul>			

**APPENDIX 2****EAS FHSC EXECUTIVE COMMITTEE**

---

- Prof. Kausik K. Ray, EAS FHSC lead. Imperial College London, London, UK.
- Prof. Alberico L. Catapano, University of Milan, Milan, Italy.
- Dr. Tomas Freiburger, Masaryk University, Brno, Czech Republic.
- Prof. G. Kees Hovingh, Academic Medical Center, Amsterdam, The Netherlands.
- Prof. John J. Kastelein, Academic Medical Center, Amsterdam, The Netherlands.
- Prof. Pedro Mata, Fundación Hipercolesterolemia Familiar, Madrid, Spain.
- Prof. Frederick J. Raal, University of the Witwatersrand, Johannesburg, South Africa.
- Prof. Raul D. Santos, University of São Paulo, São Paulo, Brazil.
- Dr. Handrean Soran, University of Manchester, Manchester, UK.
- Prof. Gerald F. Watts, University of Western Australia, Perth, Australia.

**APPENDIX 3****EAS FHSC STEERING COMMITTEE (NATIONAL LEAD INVESTIGATORS/COUNTRY-LEADS)**


---

Updated at the time of the present submission

Region/organisation	NLI/CL
Argentina	Dr. P. Corral
Australia	Prof. G.F. Watts
Austria	Prof. H. Dieplinger
Belgium	Prof. O. Descamps
Brazil	Prof. R.D. Santos
Canada	Prof. J. Genest
Chile	Dr. R. Alonso
China	Dr. L. Jiang
Czech Republic	Dr. T. Freiburger
Denmark	Prof. B.G. Nordestgaard
Finland	Dr. E. Widén
France	Prof. E. Bruckert
Germany	Prof. U. Laufs, Prof. H. Schunkert
Greece	Dr. E. Liberopoulos
Iran	Dr. A. Sahebkar
Ireland, Republic of	Dr. V. Maher
Israel	Dr. R. Durst
Italy	Prof. A.L. Catapano
Japan	Prof. M. Harada-Shiba, Prof. S. Yamashita
Latvia	Prof. G. Latkovskis
Lebanon	Prof. M. Abifadel
Malta	Dr. M. Tilney
Mexico	Dr. C.A. Aguilar-Salinas
Netherlands	Prof. G.K. Hovingh
Norway	Dr. M.P. Bogsrud
Oman	Prof. K. Al Rasadi
Poland	Prof. M. Banach
Portugal	Prof. M. Bourbon, Dr. I.M. Gaspar

Russia	Prof. A. Susekov
Saudi Arabia	Dr. F. Alnouri
Singapore	Prof. C. Lam
South Africa	Prof. F.J. Raal
Spain	Prof. P. Mata
Sweden	Prof. L. Nilsson
Switzerland	Prof. A.R. Miserez
Taiwan	Dr. T.C. Su
Tunisia	Prof. M.N. Slimane
Turkey	Prof. M. Kayikcioglu
United Arab Emirates	Prof. A. Shehab
United Kingdom	Dr. H. Soran
Uruguay	Dr. M. Stoll
Venezuela	Dr. N. Majano
DACH Society	Prof. W. März (Germany)
<u>→ Partnership with ScreenPro FH Programme</u>	
ScreenPro FH Lead	Prof. R. Ceska (Czech Republic)
Bosnia & Herzegovina	Assoc Prof. B. Pojskic
Croatia	Prof. Z. Reiner
Greece	Prof. A.D. Tselepis
Hungary	Prof. G. Paragh
Kyrgyzstan	Prof. E. Mirrakhimov
Lithuania	Prof. Z. Petrulioniene
Romania	Prof. D. Gaita
Russia	Prof. M.V. Ezhov
Slovakia	Dr. B. Vohnout
Slovenia	Prof. Z. Fras
Ukraine	Prof. O. Mitchenko
<u>→ Partnership with The 10 Countries Study</u>	
10 Countries Study Lead	Prof. G.F. Watts (Australia)
China (Beijing)	Prof. J. Lin
China (Hong Kong)	Prof. B. Tomlinson
Malaysia	Prof. H. Nawawi
Philippines	Dr. L.E. Santos
South Africa	Prof. A.D. Marais
Vietnam	Pending